HIM
DNLI icon

Hillsdale Investment Management’s Denali Therapeutics DNLI Stock Holding History

Hillsdale Investment Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-25,700
Closed -$789K – 570
2022
Q3 		$789K Buy
+25,700
New +$836K 0.07% 195
2021
Q3 		– Sell
-17,200
Closed -$1.35M – 576
2021
Q2 		$1.35M Sell
17,200
-1,000
-5% -$61.9K 0.11% 177
2021
Q1 		$1.04M Buy
+18,200
New +$1.22M 0.09% 246

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Hillsdale Investment Management's DNLI Position: Q4 2022 in Review

Hillsdale Investment Management sold out of Denali Therapeutics (DNLI) in Q4 2022, closing a stake of 25,700 shares — an estimated $789K sold.

Hillsdale Investment Management first reported a position in DNLI in Q1 2021 and held it in 3 quarters. The position peaked at $1.35M in Q2 2021. 199 funds tracked by Wall St. Rank hold DNLI as of Q4 2022.

  • Hillsdale Investment Management reported no remaining Denali Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Hillsdale Investment Management sold 25,700 Denali Therapeutics shares in Q4 2022, an estimated $789K.
  • Hillsdale Investment Management first reported a position in Denali Therapeutics in Q1 2021 and held it in 3 quarters.
  • Hillsdale Investment Management's Denali Therapeutics position peaked at $1.35M in Q2 2021.
  • 199 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2022.

Based on Hillsdale Investment Management's 13F filing for Q4 2022, filed 13 Feb 2023.